These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 7830029)

  • 1. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
    Vuorio AF; Ojala JP; Sarna S; Turtola H; Tikkanen MJ; Kontula K
    J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study.
    Vuorio AF; Turtola H; Piilahti KM; Repo P; Kanninen T; Kontula K
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3127-38. PubMed ID: 9409302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia.
    Gylling H; Aalto-Setälä K; Kontula K; Miettinen TA
    Arterioscler Thromb; 1991; 11(5):1368-75. PubMed ID: 1911722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?
    Leren TP; Hjermann I
    Eur J Clin Invest; 1995 Dec; 25(12):967-73. PubMed ID: 8719939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ; Pilcher G; Rubinsztein DC; Lingenhel A; Utermann G
    Atherosclerosis; 1997 Feb; 129(1):97-102. PubMed ID: 9069523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven DNA polymorphisms in the LDL receptor gene: application to the study of familial hypercholesterolemia in Spain.
    Chaves FJ; Puig O; García-Sogo M; Real J; Gil JV; Ascaso J; Carmena R; Armengod ME
    Clin Genet; 1996 Jul; 50(1):28-35. PubMed ID: 8891383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
    Carmena R; Roederer G; Mailloux H; Lussier-Cacan S; Davignon J
    Metabolism; 1993 Jul; 42(7):895-901. PubMed ID: 8345800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland.
    Koivisto UM; Turtola H; Aalto-Setälä K; Top B; Frants RR; Kovanen PT; Syvänen AC; Kontula K
    J Clin Invest; 1992 Jul; 90(1):219-28. PubMed ID: 1634609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia.
    Vuorio AF; Turtola H; Kontula K
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3332-7. PubMed ID: 9409330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia.
    Salazar LA; Cavalli SA; Hirata MH; Diament J; Forti N; Giannini SD; Nakandakare ER; Bertolami MC; Hirata RD
    Braz J Med Biol Res; 2000 Nov; 33(11):1301-4. PubMed ID: 11050659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia.
    Jensen HK; Jensen LG; Meinertz H; Hansen PS; Gregersen N; Faergeman O
    Atherosclerosis; 1999 Oct; 146(2):337-44. PubMed ID: 10532689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia.
    Vohl MC; Gaudet D; Moorjani S; Tremblay G; Perron P; Gagné C; Lesiège D; Bergeron J; Lupien PJ; Després JP
    Eur J Clin Invest; 1997 May; 27(5):366-73. PubMed ID: 9179542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
    García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
    Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
    Jeenah M; September W; Graadt van Roggen F; de Villiers W; Seftel H; Marais D
    Atherosclerosis; 1993 Jan; 98(1):51-8. PubMed ID: 8457250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.